Iovance Biotherapeutics jumps as analysts lift targets and short interest fuels momentum

Iovance Biotherapeutics (IOVA) is up 12.0% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to a fresh wave of bullish sell-side updates following the company’s late-February results, with at least one firm raising its price target while keeping a neutral stance. With short interest reported at elevated levels, the stock may also be seeing momentum-driven buying and short-covering after recent upside volatility.

Details:

A sell-side analyst increased Iovance’s price target on March 5 following what they characterized as fundamental improvement in Q4 2025, while maintaining the same rating.

Iovance’s Q4 2025 report showed revenue above expectations and management pointed to increased commercial uptake for Amtagvi across treatment centers.

Short interest has been cited as unusually high for the stock, which can mechanically amplify upside moves when prices rise quickly.

The company recently disclosed upcoming March 2026 investor-conference presentations, which can draw incremental attention to updated commercial and pipeline messaging.

Sources:

GlobeNewswire, Insider Monkey, MarketBeat, Finviz

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$IOVA Hedge Fund Activity

We have seen 151 institutional investors add shares of $IOVA stock to their portfolio, and 135 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

BANK OF AMERICA CORP /DE/ added 7,998,583 shares (+127.4%) to their portfolio in Q4 2025, for an estimated $21,836,131
STATE STREET CORP added 6,851,486 shares (+51.5%) to their portfolio in Q4 2025, for an estimated $18,704,556
HRT FINANCIAL LP added 3,986,314 shares (+1078.3%) to their portfolio in Q4 2025, for an estimated $10,882,637
D. E. SHAW & CO., INC. added 3,753,586 shares (+4925.4%) to their portfolio in Q4 2025, for an estimated $10,247,289
MORGAN STANLEY added 3,610,277 shares (+64.7%) to their portfolio in Q4 2025, for an estimated $9,856,056
BLACKROCK, INC. added 3,561,836 shares (+13.7%) to their portfolio in Q4 2025, for an estimated $9,723,812
VANGUARD GROUP INC added 3,148,096 shares (+13.1%) to their portfolio in Q4 2025, for an estimated $8,594,302

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$IOVA Analyst Ratings

Wall Street analysts have issued reports on $IOVA in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Barclays issued a "Overweight" rating on 11/24/2025
Chardan Capital issued a "Buy" rating on 11/06/2025
HC Wainwright & Co. issued a "Buy" rating on 10/29/2025

To track analyst ratings and price targets for $IOVA, check out Quiver Quantitative's $IOVA forecast page.

$IOVA Price Targets

Multiple analysts have issued price targets for $IOVA recently. We have seen 5 analysts offer price targets for $IOVA in the last 6 months, with a median target of $9.0.

Here are some recent targets:

David Dai from UBS set a target price of $4.0 on 03/05/2026
Reni J. Benjamin from Citizens set a target price of $5.0 on 03/03/2026
Etzer Darout from Barclays set a target price of $11.0 on 02/25/2026
Geulah Livshits from Chardan Capital set a target price of $17.0 on 11/06/2025
Joseph Pantginis from HC Wainwright & Co. set a target price of $9.0 on 10/29/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.